Postherpetic neuralgia.
Wareham
David
D
Queen Mary University of London & Barts & The London NHS Trust, London, UK.
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000588:Amines / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D000077595:Famciclovir; D000077206:Gabapentin; D006801:Humans; D051474:Neuralgia, Postherpetic / Q000188:drug therapy* / Q000517:prevention & control; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D000929:Antidepressive Agents, Tricyclic; D000998:Antiviral Agents; D003509:Cyclohexanecarboxylic Acids; D001086:Arabinofuranosyluracil; D015075:2-Aminopurine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; C067854:5-propynylarabinofuranosyluracil; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir